S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Zymeworks (ZYME) Stock Forecast, Price & News

+0.17 (+2.92%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.92 million shs
Average Volume
1.59 million shs
Market Capitalization
$346.05 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

Zymeworks logo

About Zymeworks

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.


Zymeworks (NYSE:ZYME) Upgraded to "Buy" by Guggenheim
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$26.68 million
Book Value
$4.89 per share


Net Margins
Pretax Margin




Free Float
Market Cap
$346.05 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.27 out of 5 stars

Medical Sector

306th out of 1,420 stocks

Pharmaceutical Preparations Industry

117th out of 679 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Zymeworks (NYSE:ZYME) Frequently Asked Questions

Is Zymeworks a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Zymeworks stock.
View analyst ratings for Zymeworks
or view top-rated stocks.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Zymeworks

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) announced its quarterly earnings data on Thursday, February, 24th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.11. The business earned $19.87 million during the quarter, compared to analyst estimates of $12.69 million. Zymeworks had a negative net margin of 858.18% and a negative trailing twelve-month return on equity of 84.77%.
View Zymeworks' earnings history

What price target have analysts set for ZYME?

7 brokerages have issued 1 year price objectives for Zymeworks' stock. Their forecasts range from $14.00 to $48.00. On average, they anticipate Zymeworks' share price to reach $31.63 in the next year. This suggests a possible upside of 428.0% from the stock's current price.
View analysts' price targets for Zymeworks
or view top-rated stocks among Wall Street analysts.

Who are Zymeworks' key executives?
Zymeworks' management team includes the following people:
  • Mr. Neil A. Klompas C.A., CPA, CA, CPA, Chief Operating Officer (Age 50, Pay $589.86k) (LinkedIn Profile)
  • Dr. Ali Tehrani Ph.D., Advisor (Age 50, Pay $877.66k)
  • Mr. Kenneth H. Galbraith C.A., Pres, CEO & Chairman (Age 59)
  • Mr. Chris Astle Ph.D., Sr. VP & CFO
  • Jack W. Spinks, Mang. of Investor Relations
  • Mr. Daniel Dex J.D., Ph.D., VP of Legal & Corp. Sec.
  • Mr. Mark Hollywood, Sr. VP of Technical & Manufacturing Operations (Age 52)
  • Dr. Bruce Hart Ph.D., Sr. VP of Regulatory
  • Dr. Neil Josephson M.D., Chief Medical Officer (LinkedIn Profile)
  • Dr. David Poon Ph.D., VP of Bus. Devel. and Alliance Management
What is Ali Tehrani's approval rating as Zymeworks' CEO?

9 employees have rated Zymeworks CEO Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among Zymeworks' employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Eventide Asset Management LLC (9.31%), Woodline Partners LP (3.84%), Wellington Management Group LLP (2.04%), Alyeska Investment Group L.P. (2.02%), Maven Securities LTD (1.75%) and BlackRock Inc. (1.69%). Company insiders that own Zymeworks stock include Ali Tehrani, Diana Hausman, James Priour, Kathryn O'driscoll, Neil A Klompas and Neil Josephson.
View institutional ownership trends for Zymeworks

Which major investors are selling Zymeworks stock?

ZYME stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Wellington Management Group LLP, Raymond James & Associates, Jane Street Group LLC, Picton Mahoney Asset Management, and Group One Trading L.P.. Company insiders that have sold Zymeworks company stock in the last year include Ali Tehrani, and Neil A Klompas.
View insider buying and selling activity for Zymeworks
or view top insider-selling stocks.

Which major investors are buying Zymeworks stock?

ZYME stock was bought by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Maven Securities LTD, Woodline Partners LP, JPMorgan Chase & Co., Alyeska Investment Group L.P., Renaissance Technologies LLC, National Bank of Canada FI, and Walleye Capital LLC.
View insider buying and selling activity for Zymeworks
or or view top insider-buying stocks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $5.99.

How much money does Zymeworks make?

Zymeworks has a market capitalization of $346.05 million and generates $26.68 million in revenue each year.

How many employees does Zymeworks have?

Zymeworks employs 455 workers across the globe.

What is Zymeworks' official website?

The official website for Zymeworks is www.zymeworks.com.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company can be reached via phone at (604) 678-1388, via email at [email protected], or via fax at 604-737-7077.

This page was last updated on 5/21/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.